

Corporate Action Notice



July 6, 2012

Ratio Change and Stock Distribution

RE: Aspen Pharmacare

DR CUSIP: 04530Y106
DR ISIN: US US04530Y1064
DR Ticker Symbol: APNHY
Ratio (DRs: Underlying Shares): 1:5

Please be advised that The Bank of New York Mellon, as Depositary, will change the ratio of the Aspen Pharmacare, Depositary Receipts ("DR") program from 1 DSs representing 5 Common shares to 1 DS representing 1 Common share, effective July 18, 2012.

The ratio change will occur simultaneously with a 400% DS distribution (or 4 additional DSs for each one DS held).

Please note the following:

DR Record Date:	July 16, 2012
DR Payable Date:	July 17, 2012
DR Distribution Rate:	400% Distribution (or 4 additional for each 1 DS held)
Old Ratio:	1 DR: 5 Common share
New Ratio:	1 DS: 1 Common Share
DR Ratio Change Effective Date	July 18, 2012

Please note: A ratio change may impact the fees payable by ADR investors.

Books will be closed from July 17, 2012 and will reopen on July 23, 2012 for Issuance and Cancellation transactions.

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Ravi Davis
Vice President
+1 212 815-4245
Ravi.davis@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Joe Oakenfold
Vice President
+852 2 840 9717
joe.oakenfold@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers.

This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.